# A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

> **NCT06610201** · — · RECRUITING · sponsor: **Hemab ApS** · enrollment: 200 (estimated)

## Conditions studied

- Von Willebrand Disease (VWD)
- Von Willebrand Disease (VWD), Type 1
- Von Willebrand Disease (VWD), Type 2
- Von Willebrand Disease (VWD), Type 3
- Von Willebrand Disease, Type 2A
- Von Willebrand Disease, Type 2M
- Von Willebrand Disease, Type 2N

## Interventions

- **OTHER:** Clinical outcomes of patients with VWD, Type 1
- **OTHER:** Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3

## Key facts

- **NCT ID:** NCT06610201
- **Lead sponsor:** Hemab ApS
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06610201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06610201, "A Study of Bleeding and Treatment in Participants With Von Willebrand Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06610201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*